SCHEMBL285357

SCHEMBL285357

O=C(O)[C@@H]1CC=CN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL230454 1.00
Ammonia Solution, Strong SCHEMBL2329454 0.98
SCHEMBL27574454 0.98
SCHEMBL15150021 0.78
SCHEMBL17627904 0.78
SCHEMBL15149517 0.78
SCHEMBL325433 0.76
SCHEMBL15330716 0.76
SCHEMBL8183729 0.76
Hydrochloric Acid SCHEMBL1703549 0.75 CYP2D6 (0.37)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2861745-A2 METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE Invista Technologies S.à.r.l. (CH) 2015-04-22 EP claimed
EP-2785848-A2 METHODS FOR BIOSYNTHESIZING 1,3BUTADIENE INVISTA Technologies S.à.r.l. (CH) 2014-10-08 EP claimed
WO-2013188546-A2 METHODS FOR BIOSYNTHESIZING 1,3 BUTADIENE INVISTA TECHNOLOGIES S.À.R.L. (CH) 2013-12-19 WO claimed
WO-2013082542-A2 METHODS FOR BIOSYNTHESIZING 1,3BUTADIENE INVISTA NORTH AMERICA S.A.R.L. (US) 2013-06-06 WO claimed
EP-4423259-A1 ENGINEERED ENZYMES AND METHODS OF MAKING AND USING Genomatica, Inc. (US) 2024-09-04 EP disclosed
EP-4388319-A1 PERSONALIZED MODULATION THERAPY FOR CANCER Faeth Therapeutics, Inc. (US) 2024-06-26 EP disclosed
EP-4277976-A1 METHODS AND COMPOSITIONS FOR MAKING AMIDE COMPOUNDS Genomatica, Inc. (US) 2023-11-22 EP disclosed
WO-2023076966-A1 ENGINEERED ENZYMES AND METHODS OF MAKING AND USING GENOMATICA, INC. (US) 2023-05-04 WO disclosed
WO-2023023147-A1 PERSONALIZED MODULATION THERAPY FOR CANCER FAETH THERAPEUTICS, INC. (US) 2023-02-23 WO disclosed
WO-2022155554-A1 METHODS AND COMPOSITIONS FOR MAKING AMIDE COMPOUNDS GENOMATICA, INC. (US) 2022-07-21 WO disclosed
EP-3959310-A1 ENGINEERED TRANSAMINASE AND METHODS OF MAKING AND USING Genomatica, Inc. (US) 2022-03-02 EP disclosed
EP-3959327-A1 ENGINEERED TRANS-ENOYL COA REDUCTASE AND METHODS OF MAKING AND USING Genomatica, Inc. (US) 2022-03-02 EP disclosed
WO-2012129450-A1 MICROBIAL PRODUCTION OF CHEMICAL PRODUCTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS OPX BIOTECHNOLOGIES, INC. (US) 2012-09-27 WO disclosed
EP-2459531-A2 SYNTHESIS AND USE OF VILDAGLIPTIN FOR THE PREPARATION OF PHARMACEUTICAL DOSAGE FORMS KRKA, D.D., Novo Mesto (SI) 2012-06-06 EP disclosed
EP-2427544-A1 MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID Genomatica, Inc. (US) 2012-03-14 EP disclosed
WO-2011012322-A9 SYNTHESIS AND USE OF VILDAGLIPTIN FOR THE PREPARATION OF PHARMACEUTICAL DOSAGE FORMS KRKA, D.D., NOVO MESTO (SI) 2011-08-11 WO disclosed
WO-2011012322-A2 SYNTHESIS AND USE OF VILDAGLIPTIN FOR THE PREPARATION OF PHARMACEUTICAL DOSAGE FORMS KRKA, D.D., NOVO MESTO (SI) 2011-02-03 WO disclosed
WO-2010129936-A1 MICROORGANISMS AND METHODS FOR THE BIOSYNTHESIS OF ADIPATE, HEXAMETHYLENEDIAMINE AND 6-AMINOCAPROIC ACID GENOMATICA, INC. (US) 2010-11-11 WO disclosed
WO-2009052186-A1 METABOLOMICS-BASED IDENTIFICATION OF DISEASE-CAUSING AGENTS GEORGIA TECH RESEARCH CORPORATION (US) 2009-04-23 WO disclosed
EP-0931069-B1 PROCESS FOR PREPARING AMIDINES BASF AG (DE) 2000-11-29 EP disclosed